Anti-8-OHdG/FITC,熒光素標(biāo)記兔抗8-羥基脫氧鳥苷蛋白抗體

>>>>>>>>> 點擊查看

產(chǎn)品名稱：Anti-8-OHdG/FITC,熒光素標(biāo)記兔抗8-羥基脫氧鳥苷蛋白抗體  

中文名稱：FITC標(biāo)記的8-羥基脫氧鳥苷抗體

英文名稱：Anti-8-OHdG/8 Hydroxyguanosine/FITC 

產(chǎn)品編號：BYK-1278R-FITC 

產(chǎn)品別名： 8-Hydroxy-2'-deoxyguanosine; 8-Hydroxydeoxyguanosine; 8 hydroxy 2’ deoxyguanosine; 8 hydroxyguanine; 8 hydroxyguanosine; 8 OHG; 8-OHG; 8OG; 8OHdG; 8OHG 

本公司另供應(yīng)“FITC標(biāo)記的8-羥基脫氧鳥苷抗體”的其他標(biāo)記有：Alexa Fluor 350     Alexa Fluor 488    Alexa Fluor 555   Alexa Fluor 647    AP    APC    Biotin   Cy3    Cy5    Cy5.5   Cy7    FITC     Gold   HRP   PE   PE-Cy3   PE-CY5   PE-CY5.5   PE-CY7    RBITC.

產(chǎn)品規(guī)格：100ug

產(chǎn)品濃度：  2mg/1ml

亞 型：IgG

純化方法：affinity purified by Protein A

儲 存 液：0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

產(chǎn)品類型：標(biāo)記一抗

抗體來源：Rabbit

克隆類型：polyclonal

保存條件：Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Anti-8-OHdG/FITC,熒光素標(biāo)記兔抗8-羥基脫氧鳥苷蛋白抗體   相關(guān)產(chǎn)品：

Anti-CCL14/HCC-1（C-C motif chemokine 14）  嗜酸粒細(xì)胞趨化蛋白14抗體
Anti-CCL15/MIP5（C-C motif chemokine 15）  巨噬細(xì)胞炎性蛋白15
Anti-CCL16/HCC-4（C-C motif chemokine 16）  巨噬細(xì)胞炎性蛋白16抗體
Anti-CCL17/TARC（C-C motif chemokine 17）  胸腺活化調(diào)節(jié)趨化因子抗體
Anti-CCL21/6Ckine（Chemokine （C-C motif） ligand 21）  淋巴細(xì)胞趨化因子CCL21抗體
Anti-CCL22/MDC（small inducible cytokine A22 precursor）  嗜酸粒細(xì)胞趨化蛋白22抗體
Anti-CCL20/MIP3α（Macrophage inflammatory ptotein 3 alpha）  巨噬細(xì)胞炎性蛋白20抗體
Anti-CCL23/MPIF-1/MIP3（Macrophage Inflammatory Protein 3）  巨噬細(xì)胞炎性蛋白抗體
Anti-CCL24/Eotaxin-2（C-C motif chemokine 24）  嗜酸粒細(xì)胞趨化蛋白24抗體
Anti-MIP-3 beta/ELC/CCL19（Macrophage Inflammatory Protein 3 β）   巨噬細(xì)胞炎性蛋白19 抗體

  的產(chǎn)品介紹：
8-Hydroxydeoxyguanosine （8OHdG） is a modified base that occurs in DNA due to attack by hydroxyl radicals that are formed as byproducts and intermediates of aerobic metabolism and during oxidative stress. There is increasing evidence to support the involvement of free radical reactions in the damage of biomolecules that eventually lead to several diseases in humans, such as atherosclerosis, cerebral and heart ischemia-reperfusion injury, cancer, rheumatoid arthritis, inflammation, diabetes, aging, and neurodegenerative conditions, such as Alzheimer's disease